[A26-03] Daratumumab (smouldering multiple myeloma) – Addendum to Project A25-109
Last updated 19.02.2026
Project no.:
A26-03
Commission:
Commission awarded on 13.01.2026 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adult patients with smouldering multiple myeloma who are at high risk of developing multiple myeloma
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
DOI:
https://doi.org/10.60584/A26-03
| Project no. | Title | Status |
|---|---|---|
| A25-109 | Daratumumab (smouldering multiple myeloma) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
19-02-2026 A G-BA decision was published.
G-BA documents on this decision